# Toward phase contribution assessment in perioperative oncology: insights from NSCLC and a proposal for broader implementation

**Authors:** Hui-Yao Huang, Yan-Jie Han, Yu Tang, Ning Jiang, Da-Wei Wu, Ning Li

PMC · DOI: 10.1186/s40779-025-00622-2 · Military Medical Research · 2025-07-31

## Full-text entities

- **Diseases:** rectal cancer (MESH:D012004), cancer (MESH:D009369), melanoma (MESH:D008545), NSCLC (MESH:D002289), esophageal cancer (MESH:D004938), triple-negative breast cancer (MESH:D064726), toxicity (MESH:D064420), urothelial carcinoma (MESH:D014523), COVID-19 (MESH:D000086382)
- **Chemicals:** nivolumab (MESH:D000077594), durvalumab (MESH:C000613593), Immune checkpoint (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12312453/full.md

## References

2 references — full list in the complete paper: https://tomesphere.com/paper/PMC12312453/full.md

---
Source: https://tomesphere.com/paper/PMC12312453